SU11248: An oral multitargeted tyrosine kinase inhibitor with promising activity in metastatic renal cell carcinoma

被引：0
|
作者：
Sternberg, CN [1 ]
机构：
[1] Can Camillo & Forlanini Hosp, Dept Med Oncol, I-00152 Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：17 / 17
页数：1
相关论文
共 50 条
  • [1] The multitargeted kinase inhibitor sunitinib malate (SU11248): soluble protein biomarkers of pharmacodynamic activity in patients with metastatic renal cell cancer
    DePrimo, S.
    Bello, C.
    Smeraglia, J.
    Shalinsky, D.
    Freddo, J.
    Baum, C.
    Rini, R.
    Michaelson, M.
    Motzer, R.
    Spinella, D.
    EJC SUPPLEMENTS, 2005, 3 (02): : 420 - 420
  • [2] Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248
    Potapova, Olga
    Laird, A. Douglas
    Nannini, Michelle A.
    Barone, Angela
    Li, Guangmin
    Moss, Katherine G.
    Cherrington, Julie M.
    Mendel, Dirk B.
    MOLECULAR CANCER THERAPEUTICS, 2006, 5 (05) : 1280 - 1289
  • [3] Nonclinical safety evaluation of sunitinib (SU11248; SUTENT), a novel multitargeted tyrosine kinase inhibitor for treatment of cancer
    Patyna, S.
    Heward, J. K.
    Evering, W.
    TOXICOLOGIC PATHOLOGY, 2007, 35 (01) : 188 - 188
  • [4] Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
    Faivre, S
    Delbaldo, C
    Vera, K
    Robert, C
    Lozahic, S
    Lassau, N
    Bello, C
    Deprimo, S
    Brega, A
    Massimini, G
    Armand, JP
    Scigalla, P
    Raymond, E
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) : 25 - 35
  • [5] Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
    Motzer, RJ
    Michaelson, MD
    Redman, BG
    Hudes, GR
    Wilding, G
    Figlin, RA
    Ginsberg, MS
    Kim, ST
    Baum, CM
    DePrimo, SE
    Li, JZ
    Bello, CL
    Theuer, CP
    George, DJ
    Rini, BI
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) : 16 - 24
  • [6] Phase II study of SU11248, a multitargeted tyrosine kinase inhibitor (TKI) in patients (pts) with previously treated metastatic breast cancer (MBC).
    Miller, KD
    Burstein, HJ
    Elias, AD
    Rugo, HS
    Cobleigh, MA
    Wolff, AC
    Eisenberg, PD
    Collier, M
    Adams, BJ
    Baum, CM
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S61 - S61
  • [7] Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor
    Alyssa M Morimoto
    Nguyen Tan
    Kristina West
    Grant McArthur
    Guy C Toner
    William C Manning
    Beverly D Smolich
    Julie M Cherrington
    Oncogene, 2004, 23 : 1618 - 1626
  • [8] Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor
    Morimoto, AM
    Tan, N
    West, K
    McArthur, G
    Toner, GC
    Manning, WC
    Smolich, BD
    Cherrington, JM
    ONCOGENE, 2004, 23 (08) : 1618 - 1626
  • [9] Pazopanib: An Oral Multitargeted Tyrosine Kinase Inhibitor for Use in Renal Cell Carcinoma
    LaPlant, Kourtney D.
    Louzon, Paige D.
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (06) : 1054 - 1060
  • [10] Preclinical evaluation of the tyrosine kinase inhibitor SU11248 for the treatment of breast cancer
    Abrams, TJ
    Murray, LJ
    Pryer, NK
    Garcia, R
    Potapova, O
    Laird, AD
    Manning, JWC
    Pesenti, E
    Cherrington, JM
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S75 - S75
12345